Maybe Logo Early Access

Tools / Inside Trading Tracker

Inside Trading Tracker

Track insider trading activity at publicly traded companies to understand how executives are trading their shares.

    2 (IPSC) Insider Trading Activity

    Healthcare • Biotechnology • 152 employees

    Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

    Total Value

    -$27,548.90

    Total Shares

    112,849

    Average Trade Value

    -$2,295.74

    Most Active Insider

    Carr Douglas

    Total Activity: $21,805

    Largest Single Transaction

    $20,930

    by Carr Douglas on Nov 1, 2024

    30-Day Activity

    0 Transactions

    Volume: 0 shares
    Value: $0

    Name
    Position
    Date
    Shares
    Value
    Holdings
    Type
    SVP Finance Operations
    Officer
    Nov 4, 2024 283 $347 317,147 (-0.1%) Sale
    Chief Operations Officer
    Officer
    Nov 4, 2024 1,033 $1,267 135,130 (-0.8%) Sale
    SVP Finance Operations
    Officer
    Nov 1, 2024 16,611 $20,930 317,430 (-5.2%) Payment of Exercise Price
    Chief Finanical Officer
    Officer
    Oct 14, 2024 60,148 $0 60,148 (+100.0%) Grant
    Chief Scientific Officer
    Officer
    Oct 1, 2024 74,376 $10,000 210,806 (+35.3%) Grant
    Director
    Sep 12, 2024 5,000 $7,657 5,000 (+100.0%) Purchase
    Chief Operations Officer
    Officer
    Aug 5, 2024 1,073 $1,960 136,163 (-0.8%) Sale
    SVP Finance Operations
    Officer
    Aug 5, 2024 289 $528 334,041 (-0.1%) Sale
    See Remarks
    Officer
    Jul 26, 2024 586 $1,465 274,933 (-0.2%) Sale
    See Remarks
    Officer
    Jul 24, 2024 1,600 $4,029 275,519 (-0.6%) Sale
    See Remarks
    Officer
    Jul 23, 2024 200 $500 277,119 (-0.1%) Sale
    See Remarks
    Officer
    Jun 20, 2024 5,000 $14,179 277,319 (-1.8%) Sale